True - MSB maybe couldn't get the 300 patients required. Therefore the reduction in patients will change the recovery ratio proposed within the original study. They are still continuing with the study with a reduced number of patients. What if recovery after 60 day is greater than the ratio proposed in the initial study? That would be a big success. I also note the comment that treatment for COVID is rapidly changing so the risk is in 60 day there could be something highly effective and this might all be a waste of time... It a risky time to hold and buy - but at these prices load up!!
Ann: Mesoblast Update on COVID-19 ARDS Trial, page-207
-
- There are more pages in this discussion • 869 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.01 |
Change
0.030(3.06%) |
Mkt cap ! $1.153B | |||
| Open | High | Low | Value | Volume |
| $1.01 | $1.04 | 99.0¢ | $5.111M | 5.050M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 211966 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.02 | 136540 | 9 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |